Wegovy prices in the UK: what the numbers really tell you

The misconception: a low headline price is a straightforward saving

The most persistent myth about Wegovy prices is that the cheapest listing equals the best deal. It almost never does. A headline figure stripped of consultation fees, prescription charges and delivery costs can look attractive until those extras arrive. One question our prescribers hear most weeks is: 'I found it for £X somewhere, why is your price different?' The honest answer is usually that the £X figure covers the medicine alone, while a complete service wraps a clinical consultation, a GPhC-registered prescriber's review, the prescription itself and tracked delivery into a single amount.

There is also a safety dimension that price comparisons rarely mention. Semaglutide is a Prescription-Only Medicine; if a price seems detached from any clinical process, that is worth pausing over. The MHRA has warned publicly about counterfeit weight-loss pens circulating online, fake products that have, in some cases, contained insulin rather than semaglutide. If you are comparing prices, it is worth reading up on how to use Wegovy safely alongside any cost research, and verifying that any pharmacy you consider is registered on the GPhC register at pharmacyregulation.org.

Wegovy's licensed titration schedule runs from 0.25 mg upward through 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, with the MHRA having approved a 7.2 mg maintenance dose in January 2026 and a dedicated single-dose 7.2 mg pen in April 2026. Lower doses cost less per pen, so where you are in your titration genuinely affects your monthly outgoings, a prescriber-guided review before each supply is not an optional extra, it is part of why the medicine works safely.

What moved UK Wegovy prices in late 2025

From September 2025 Eli Lilly raised the UK list price of Mounjaro (tirzepatide) substantially, which drew wider attention to GLP-1 pricing in general, including Wegovy. Novo Nordisk's pricing did not move in identical lockstep, but private market rates across semaglutide products shifted as demand remained high and supply constraints persisted through much of 2024 and early 2025. The reported private market range (roughly £149 to £375 per month) reflects that landscape. Those figures are hedged deliberately: individual pharmacy pricing is not centrally published and providers review their rates independently.

For a fuller picture of how Wegovy and tirzepatide prices compare across the UK private market, the Wegovy price comparison page sets that out in detail, including what different providers typically include. It is worth reading before you commit to a provider, not after. The general semaglutide guide covers the clinical background in depth if you want to understand what you are paying for before the pricing conversation.

One practical note: Wegovy is not currently available through NHS primary care in the way that tirzepatide has been rolled out under the NICE TA1026 phased eligibility scheme. NICE's recommendation for semaglutide (TA875) requires treatment within a specialist weight management service for a maximum of two years. For most people, private prescription through a regulated pharmacy is the realistic route, and that means price is an ongoing monthly consideration, not a one-off.

What a complete Wegovy price should cover, and what to check

When you are evaluating any price, the useful question is not 'is this cheap?' but 'what does this include?' A legitimate monthly cost for Wegovy should reflect at minimum: an initial clinical consultation, identity and eligibility verification, a prescription written by a registered prescriber, the medicine itself at the relevant dose, and delivery. Ongoing clinical support (someone to contact if a side effect concerns you, a review before the next supply) matters too, though it is often the first thing cut by providers competing on price alone.

At nume, the price shown on our Wegovy treatment page covers all of that: free consultation, clinical review by a GPhC-registered Independent Prescriber, the prescription, and free next-working-day tracked delivery. We do not run discount codes or promotional pricing. That is a deliberate position, not an oversight, cheapest is not a race we entered. You can read more about how the service works and who oversees it on the about us page, or look at the clinical team profile to understand the prescribing oversight behind every consultation.

If you are trying to work out whether Wegovy is clinically appropriate for your situation before worrying about price, our weight-loss treatment overview sets out the eligibility landscape clearly, including how BMI thresholds work and what weight-related conditions qualify. Semaglutide's STEP 1 trial, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% over 68 weeks, a figure your prescriber will set in the context of your own starting point and health history.

Eligibility, the prescription process, and where pricing fits in

Wegovy is licensed for adults with a BMI of 30 or above, or 27–29.9 where at least one weight-related condition is present, conditions that include hypertension, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea and cardiovascular disease. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not decide the outcome; a prescriber looks at your full picture, including other medicines you take, your medical history and whether Wegovy is appropriate against its contraindications.

That clinical review is part of the cost, whether or not it is listed separately. If you see a price that makes no mention of a prescriber's involvement, treat that as a red flag rather than a feature. NICE's appraisal of semaglutide for weight management, TA875, sets out why clinical oversight is baked into the treatment model: the evidence base comes from trials conducted alongside lifestyle support and regular clinical monitoring, not from the medicine in isolation.

Once you know the clinical side makes sense for you, price becomes a reasonable secondary question. If you are still weighing up Wegovy or an alternative such as tirzepatide, that page sets out a direct comparison to help you decide which treatment fits your situation. The Wegovy prescribing process page explains what happens step by step from consultation to delivery, which helps set expectations about timing and what is involved before a pen reaches you. If you have questions the pages do not cover, the FAQs address the most common ones, or you can reach the team directly through the contact page. When you are ready to take the next step, checking your eligibility through a free consultation is the place to start.